Alnylam Pharmaceuticals Inc. won expanded approval for a heart drug that could be the biggest boon yet for the 23-year-old biotech and put it in competition with Pfizer Inc.
Source link
Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer
